Menu Search
Equities

Ucb SA

UNC:MUN

Ucb SA

Actions
  • Price (EUR)184.95
  • Today's Change3.10 / 1.70%
  • Shares traded60.00
  • 1 Year change+173.76%
  • Beta--
Data delayed at least 15 minutes, as of Nov 08 2024 16:26 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Ucb SA is a Belgium-based biopharmaceutical and specialty chemical company that specializes in two therapeutic areas: diseases of the central nervous system (CNS) and immunology. In the area of central nervous system disorders, the Company is focused on epilepsy, diabetic neuropathic pain, multiple sclerosis, fibromyalgia, restless legs syndrome and Parkinson’s disease, and the area of immunology includes, bone loss disorders, Crohn’s disease, rheumatoid arthritis and respiratory disease. In addition to its core fields of business, Ucb SA delivers molecule solutions to specialists for use in the treatment of severe diseases. Its product portfolio includes drugs, such as Neupro, Vimpat, Cimzia, among others. Ucb SA also operates in primary care to support specialist products that are administered by primary care physicians.

  • Revenue in EUR (TTM)5.45bn
  • Net income in EUR240.00m
  • Incorporated--
  • Employees9.08k
  • Location
    Ucb SAAllee de la Recherche, 60ANDERLECHT 1070BelgiumBEL
  • Phone+32 25599999
  • Fax+32 25599900
  • Websitehttps://www.ucb.com
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.